Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av treatment. Here we present data regarding the effect of Av treatment on migration of a non-invasive breast cancer cell line, MCF-7. The data presented hereis related to the research article "Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model" (Hajjar et al., 2018).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327074PMC
http://dx.doi.org/10.1016/j.dib.2018.12.059DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
cancer cell
12
migration non-invasive
8
non-invasive breast
8
cell mcf-7
8
data migration
4
breast
4
cancer
4
cell
4
mcf-7 treated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!